ライフサイエンスコーパス: adjusted life year

1 fectiveness ratio of pound20 000 per quality-adjusted life-year).

2 4.5% of diabetes mellitus-related disability-adjusted life years).

3 py vs warfarin therapy (7.94 vs 7.54 quality-adjusted life years).

4 ources, and impact on health status (quality-adjusted life-years).

5 $5459 per year, to reach $100000 per quality-adjusted life year.

6 from estimates of the value of a disability-adjusted life year.

7 tcome was cost (2014 US dollars) per quality adjusted life year.

8 s-to-pay threshold of AUS$30 000 per quality-adjusted life-year.

9 plus PCSK9i therapy was $337729 per quality-adjusted life-year.

10 f SDS versus TAU was pound43 603 per quality-adjusted life-year.

11 fective at pound20 000 ($26 600) per quality-adjusted life-year.

12 cin plus flucytosine was $23 842 per quality-adjusted life-year.

13 ss ratio was $782,598 per additional quality-adjusted life-year.

14 a willingness to pay of $100 000 per quality-adjusted life-year.

15 We calculated cost per quality-adjusted life-year.

16 ingness-to-pay level of $100,000 per quality-adjusted life-year.

17 -effectiveness ratio of $189,000 per quality-adjusted life-year.

18 ed societal threshold of $100000 per quality-adjusted life-year.

19 ombined burden of over 87 million disability-adjusted life years.

20 ureus infections and improvements in quality-adjusted life years.

21 s well as approximately 3% of all disability-adjusted life-years.

22 life measured in net life-years and quality-adjusted life-years.

23 ture deaths from AAA and to gain 577 quality-adjusted life-years.

24 easures of incidence, burden, and disability-adjusted life-years.

25 tio was estimated to be euro7770 per quality-adjusted life-years.

26 as the loss of both productivity and quality-adjusted life-years.

27 [standard error (SE) 0.007]), fewer quality-adjusted life years (0.023 [SE 0.007] fewer using UK EQ-

28 red with Current Pace was $68900 per quality-adjusted life-year ($38300 for black MSM) and was most s

29 ness ratio of $45,320 per additional quality-adjusted life year (= $516/0.011).

30 s at a willingness to pay of $50,000/quality-adjusted life year (86%; PCa, 2%; Ca, 12%).

31 ant differences in survival time and quality-adjusted life years according to all assessed baseline c

32 al coverage lived an average of 9.46 quality-adjusted life years after their event and incurred costs

33 trategy resulted in 9.27 per-patient quality-adjusted life years and $304,800 per patient lifetime co

34 rategy resulted in 11.48 per-patient quality-adjusted life years and $365,948 per patient lifetime co

35 y and effectiveness were measured in quality-adjusted life years and benefit in US dollars.

36 net effects of niacin-laropiprant on quality-adjusted life years and hospital care costs (2012 UK pou

37 ll coverage lived an average of 9.60 quality-adjusted life years and incurred costs of $167,401.

38 herapy compared with PRP were $55568/quality-adjusted life-year and $662978/quality-adjusted life-yea

39 ca will probably lose 2.3 million disability-adjusted life-years and US$3.5 billion of economic produ

40 ater quality-adjusted survival (0.14 quality-adjusted life years) and less resource use ($4011) per p

41 th FQN resistance, TB-related death, quality-adjusted life years, and health system costs.

42 del outputs included lifetime costs, quality-adjusted life years, and lifetime risk of developing ana

43 ong-term outcomes, such as survival, quality-adjusted life-years, and functional status; receipt of s

44 lculated outcomes included survival, quality-adjusted life-years, and incremental cost-effectiveness.

45 Lifetime net quality-adjusted life-years are positive for most adults initiat

46 Thirty-seven percent of disability-adjusted-life-years arise from human infectious diseases

47 strategies still cost >$200 000 per quality-adjusted life-year as that risk approached 99%.

48 cost-effectiveness ratio = $197,906/quality-adjusted life year at mean age = 85 yr).

49 PCI compared with MT was $17 300 per quality-adjusted life-year at 2 years and $1600 per quality-adju

50 d life-year at 2 years and $1600 per quality-adjusted life-year at 3 years.

51 late the proportion of deaths and disability adjusted life years attributable to PM2.5 exposure from

52 anging from US$2.97 to $52.92 per disability-adjusted life year averted in the 15 countries analysed.

53 d 5,000 international dollars per disability-adjusted life year averted, and was consistently preferr

54 in order to explore the impact on disability-adjusted life years averted, program cost, and program d

55 spective (saving US$4.0-300.0 per disability-adjusted life-year averted in the countries simulated).

56 o estimate the costs and cost per disability-adjusted life-year averted of introducing Xpert as the i

57 re cost-effective at $205 to $272/disability-adjusted life-year averted, which was $142 to $182 less

58 n averted, and $351 (290-424) per disability-adjusted life-year averted.

59 We estimated health effects (ie, disability-adjusted life-years averted) and resource implications f

60 ies would result in >0.53 million disability-adjusted-life-years averted over 2022-2042, with a reduc

61 h UC was $3428.71 to $6857.68 per disability-adjusted life year avoided, and $0.80 to $1.61 per PTSD-

62 lifetime costs by $419 and increased quality-adjusted life years by 0.16.

63 , universal decolonization increased quality-adjusted life years by 1.06% (95% CI, 1.02-1.09) over ta

64 Disability-adjusted life years, combining years of life lost and ye

65 10.9 million) and health gains >2600 quality-adjusted life-years could be achieved from reinstating A

66 or the entire cohort, a total of 736 quality-adjusted life-years could be gained were treatment chang

67 S$94 (95% CrI: US$51, US$166) per Disability Adjusted Life Year (DALY) averted, PMI-funded interventi

68 valid prevalence, incidence, and disability-adjusted life year (DALY) estimates of oral conditions f

69 ories and range from 0.025 to 6.6 disability-adjusted life years (DALY) per million dollar of final e

70 of disease) on the order of 0.2-9 disability-adjusted life years (DALY) per year of operation was est

71 he incremental cost of Avahan per disability-adjusted life-year (DALY) averted versus a no-Avahan cou

72 calculated in 2014 US dollars per disability-adjusted life-year (DALY) averted.

73 Outcome measures were cost per disability-adjusted life-year (DALY) averted; cost per life-year sa

74 Disability-adjusted life-year (DALY) changes between 1990 and 2013

75 revention alone saved 3.6 million disability-adjusted life-years (DALY) per annum at an incremental c

76 er capita, and GDP per capita per disability-adjusted life-year [DALY]).

77 T and cCMV in Belgium in terms of disability-adjusted life years (DALYs) and identify data gaps.

78 odel to investigate the number of disability-adjusted life years (DALYs) averted by a hydrocelectomy

79 it costs; we quantified impact as disability-adjusted life years (DALYs) averted.

80 CVD and congenital heart anomaly disability-adjusted life years (DALYs) in the poorest countries, co

81 e vaping was derived by computing disability-adjusted life years (DALYs) lost due to exposure to seco

82 s highest in high-income regions, disability-adjusted life years (DALYs) per head are 40% higher in l

83 infections, sequelae, deaths, and Disability Adjusted Life Years (DALYs), by age and region for 2010.

84 ry, we estimated causes of death, disability-adjusted life years (DALYs), DALY-attributable risk fact

85 illnesses, sequelae, deaths, and Disability Adjusted Life Years (DALYs), for all diseases with suffi

86 Disability-adjusted life years (DALYs), years lived with disability

87 31 hazards in 2010 was 33 million Disability Adjusted Life Years (DALYs); children under five years o

88 ger impact, averting 1.10 million disability-adjusted life-years (DALYs) and 25% of expected new infe

89 Disability-adjusted life-years (DALYs) are a sum of the years lived

90 fraction (PAF) of stroke-related disability-adjusted life-years (DALYs) associated with potentially

91 e costs, productivity losses, and disability-adjusted life-years (DALYs) attributable to physical ina

92 Estimates of cases, deaths, and disability-adjusted life-years (DALYs) averted were calculated over

93 highest incremental cost: 346 000 disability-adjusted life-years (DALYs) averted with an additional c

94 s by 1.42 million (1.38-1.48) and disability-adjusted life-years (DALYs) by 27.0 million (25.8-29.1),

95 cross-tabulated the quantiles of disability-adjusted life-years (DALYs) by quintiles of DALYs annual

96 numbers of illnesses, deaths, and disability-adjusted life-years (DALYs) due to listeriosis, by synth

97 We calculated disability-adjusted life-years (DALYs) for low birthweight, severe

98 resholds of $1,582 and $4,746 per disability-adjusted life-years (DALYs) for very cost-effective and

99 lion (90.8 million 115.1 million) disability-adjusted life-years (DALYs) in 2015, representing 7.6% o

100 ved with a disability (YLDs), and disability-adjusted life-years (DALYs) in England, the UK, and 18 o

101 No studies have estimated disability-adjusted life-years (DALYs) lost due to hip fractures us

102 h overall health gains of 420-826 disability-adjusted life-years (DALYs) per 100 000 population.

103 The leading cause of disability-adjusted life-years (DALYs) was ischaemic heart disease

104 Disability-adjusted life-years (DALYs) were calculated as the sum o

105 ars lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy

106 th disability (YLDs) and 13.0% of disability-adjusted life-years (DALYs), instead of the earlier esti

107 ars lived with disability (YLDs), disability-adjusted life-years (DALYs), life expectancy, and health

108 the loss of 3.73 and 2.19 million disability-adjusted life-years (DALYs), respectively, and save >51

109 ith disability (YLD), deaths, and disability-adjusted life-years (DALYs), with 95% uncertainty interv

110 scabies, YLDs were equivalent to disability-adjusted life-years (DALYs).

111 issions, 4300 deaths, and 136 000 disability-adjusted-life-years (DALYs).

112 e described and explained, including quality-adjusted life-years, disability-adjusted life-years, dis

113 Changes in quality-adjusted life-years, disability-adjusted life-years, or

114 ding quality-adjusted life-years, disability-adjusted life-years, discounting, half-cycle correction,

115 val, 9.6 million to 11.5 million) disability-adjusted life-years due to rheumatic heart disease globa

116 health-related quality of life, and quality-adjusted life year expectancy of cancer patients admitte

117 s estimated to provide an additional quality-adjusted life year for $337729 .

118 Treatment before LT yielded more quality-adjusted life year for less money than treatment after L

119 ctiveness was measured by cumulative quality-adjusted life years for 5 years after ICU discharge.

120 The quality-adjusted life-year gain per patient was 0.11 (P<0.001) f

121 to $8,092) per patient, and the mean quality-adjusted life-year gain was 0.31 (95% CI, 0.27 to 0.35).

122 e analysis, the incremental cost per quality-adjusted life year gained by adding tomosynthesis to dig

123 ith willingness-to-pay threshold per quality-adjusted life year gained ranging from $0 to $50,000, un

124 cost-effectiveness ratios (cost per quality-adjusted life year gained) from the societal perspective

125 st-effective (less than $100 000 per quality-adjusted life year gained) over a wide range of incremen

126 pay threshold (approximately $83 000/quality-adjusted life year gained); extension to age 22 years wa

127 Outcomes were incremental cost per quality-adjusted life year gained, asthma control (ACQ score), q

128 veness ratio as measured by cost per quality-adjusted life year gained.

129 cost-effectiveness ratio of $473,400/quality-adjusted life year gained.

130 ivalent to GDP per capita in Goa-per quality-adjusted life year gained.

131 produces a mean ICER of pound19,850/quality-adjusted life years gained compared to current testing/t

132 cost-effectiveness (ICER pound15,090/quality-adjusted life years gained).

133 ylococcus aureus infections averted, quality-adjusted life years gained, and incremental cost-effecti

134 emental cost-effectiveness ratio per quality-adjusted life-year gained 36 months after treatment.

135 ber needed to treat for 10 years per quality-adjusted life-year gained of 108.

136 ber needed to treat for 10 years per quality-adjusted life-year gained of 35.

137 ber needed to treat for 10 years per quality-adjusted life-year gained of 68.

138 pectancy to 12.3 years, for $226,000/quality-adjusted life-year gained versus OHT.

139 The incremental cost per quality-adjusted life-year gained was $9333 (95% CI 3862-28 169;

140 ess ratio was favorable ($16 537 per quality-adjusted life-year gained) and remained <$20 000 per qua

141 -effectiveness (incremental cost per quality-adjusted life-year gained) was evaluated from a US persp

142 defined threshold of pound20 000 per quality-adjusted life-year gained, was 75% for closed tunnel EVH

143 of generic clopidogrel, cost $29,665/quality-adjusted life-year gained, with 99% of bootstrap estimat

144 er muL is cost-effective at $900 per quality-adjusted life-year gained.

145 tiveness ratio expressed as cost per quality-adjusted life-year gained.

146 uming a lower willingness to pay per quality-adjusted life-year gained.

147 ore transplant less than US $150 000/quality-adjusted life-year gained.

148 ers needed to treat for 10 years per quality-adjusted life-year gained.

149 95% CI, cost savings to $235613) per quality-adjusted life-year gained.

150 Benefits were measured in quality-adjusted life-years gained.

151 e annual loss of over 200 million disability-adjusted life years globally.

152 Health-adjusted life years (HALYs) gained, healthcare costs sav

153 ar gained) and remained <$20 000 per quality-adjusted life-year in most bootstrap replicates.

154 llion (0.73 million-1.98 million) disability-adjusted life-years in 2013.

155 rted approximately 5 million more disability-adjusted life-years in both China and India than a TTT a

156 ction interval: 82,000, 183,000) per quality-adjusted life-year, in comparison with the strategy of n

157 n estimated 90% of the 87 million disability-adjusted life-years incurred by surgical conditions coul

158 ness-to-pay threshold of $50 000 per quality-adjusted life year, LAA closure was cost effective 90% a

159 etheless estimate a 95% reduction in quality-adjusted life-years lost with a switch to the combined s

160 es of EUHC not encompassed by the disability-adjusted life-year metric and related cost-effectiveness

161 ncer deaths averted, life-years, and quality-adjusted life-years); number of mammograms used; harms (

162 deaths at an incremental cost per disability-adjusted life-year of $25 200.

163 vents in 6 months, and the costs per quality adjusted life-year of the two treatments.

164 s in quality-adjusted life-years, disability-adjusted life-years, or survival and mortality are some

165 r targeted decolonization and 14,562/quality-adjusted life year over screening and contact precaution

166 ons, respectively, and saved $16,203/quality-adjusted life year over targeted decolonization and 14,5

167 with an overall 28% reduction in disability-adjusted life years over the decade.

168 llion, while averting around 7000 disability-adjusted life-years over 20 years.

169 vaccine-related adverse effects, and quality-adjusted life-years owing to changing vaccine schedule.

170 , not better, or dead) and estimated quality-adjusted life-years post-transplant.

171 ingness-to-pay threshold of $100,000/quality-adjusted life year; pricing below $18,450/year is needed

172 ectiveness target of pound36 000 per quality-adjusted life-year projected over 20 years.

173 calculated the incremental cost per quality-adjusted life year (QALY) and varied model inputs in one

174 e effectiveness was measured in: (1) quality-adjusted life year (QALY) gain and (2) percent patient v

175 ios (ICERs) in 2015 U.S. dollars per quality-adjusted life year (QALY) gained and number of fragility

176 ary outcome was incremental cost per quality-adjusted life year (QALY) gained from each diagnostic st

177 determined the incremental cost per quality-adjusted life year (QALY) gained.

178 fectiveness threshold of pound20 000/quality-adjusted life year (QALY).

179 The additional quality adjusted life years (QALY) with intervention was 0.08 (9

180 s in total lifetime cost of care and quality-adjusted life years (QALY).

181 d with bevacizumab were $1110000 per quality-adjusted life-year (QALY) and $1730000 per QALY, respect

182 ment every 10 years was $111 600 per quality-adjusted life-year (QALY) compared with no assessment.

183 protection, the incremental cost per quality-adjusted life-year (QALY) gained by additional 9vHPV vac

184 miological findings and the cost per quality-adjusted life-year (QALY) gained, as well as the budget

185 miological findings and the cost per quality-adjusted life-year (QALY) gained, as well as the budget

186 redible interval 12 662-132 452) per quality-adjusted life-year (QALY) gained, pound372 207 (268 162-

187 st per life-year saved; and cost per quality-adjusted life-year (QALY) gained.

188 r FIT at a threshold of $100,000 per quality-adjusted life-year (QALY) gained.

189 ess-to-pay threshold of $100,000 per quality-adjusted life-year (QALY) gained.

190 prevented and incremental costs per quality-adjusted life-year (QALY) gained.

191 red with no screening, mean cost per quality-adjusted life-year (QALY) of screening all admissions wa

192 eported a median ICER of $13 761 per quality-adjusted life-year (QALY) saved.

193 on, or stroke), incremental cost per quality-adjusted life-year (QALY), and total effect on US health

194 mic stroke and cardiovascular death, quality-adjusted life-year (QALY), incremental cost-effectivenes

195 ness ratios, expressed as dollar per quality-adjusted life-year (QALY), were calculated with incremen

196 alth care cost per life-year and per quality-adjusted life-year (QALY).

197 ctiveness ratio (ICER) was <$100 000/quality-adjusted life-year (QALY).

198 Most ratios fell below $50,000 per quality-adjusted life-years (QALY) (73%) and $100,000/QALY (86%)

199 the reference scenario saved 51,000 quality-adjusted life-years (QALY) and had an incremental cost-e

200 disease costs were used to evaluate quality-adjusted life-years (QALY) and incremental cost-effectiv

201 iveness ratios, measured in cost per quality-adjusted life-years (QALY) gained.

202 Quality-adjusted-life-year (QALY) will be estimated taking an ar

203 d to provide a lifetime gain of 0.32 quality-adjusted life-years ([QALY]; 0.41 LY) with 3% discountin

204 old patients (less than $100 000 per quality-adjusted life-year [QALY] gained), while contrast-enhanc

205 e brief intervention ( pound2394 per quality-adjusted life-year [QALY]) and the 12-week programme ( p

206 and was cost-effective (ICER = $1915/quality-adjusted life-year [QALY]).

207 s cost-effective at 7 years ($42,994/quality-adjusted life-years [QALY]), and NOACs were cost-effecti

208 re to be a small benefit in terms of quality-adjusted life years (QALYs) (0.0325, 95% CI -0.0074 to 0

209 We measured lifetime costs and quality-adjusted life years (QALYs) (both discounted at 3% per y

210 el was developed to project lifetime quality-adjusted life years (QALYs) and costs for asymptomatic p

211 Lifetime quality-adjusted life years (QALYs) and costs were modeled for p

212 Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcare costs

213 Effects were measured in quality-adjusted life years (QALYs) and incremental cost-effecti

214 subsequently converted into gains in quality-adjusted life years (QALYs) by applying National Health

215 was developed to estimate costs and quality-adjusted life years (QALYs) comparing between the combin

216 SOF/SMV yielded lower costs and more quality-adjusted life years (QALYs) for the average subject, com

217 zon to estimate costs (2016 US$) and quality-adjusted life years (QALYs) for treatment sequences with

218 ng costs, disease-related costs, and quality-adjusted life years (QALYs) gained by preventing cardiov

219 culated the total cost and number of quality-adjusted life years (QALYs) gained.

220 expected lifetime medical costs and quality adjusted life years (QALYs) of hypothetical cohorts of i

221 y analysis estimating mean costs and quality-adjusted life years (QALYs) per patient from the perspec

222 LR produced 3.9 quality-adjusted life years (QALYs) while CLT had an additional

223 Lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effect

224 tion model projected lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effect

225 lth benefits expressed as discounted quality-adjusted life years (QALYs), costs in U.S. dollars, and

226 Quality-adjusted life years (QALYs), costs, and incremental cost

227 Corresponding increases in survival, quality-adjusted life years (QALYs), costs, and resulting budget

228 Quality-adjusted life years (QALYs), total cost, disease progres

229 ma in terms of health care costs and quality-adjusted life years (QALYs).

230 acuity were used to derive costs and quality-adjusted life years (QALYs).

231 comparing mean cumulative costs and quality-adjusted life years (QALYs).

232 lomide resulted in increases of 0.13 quality-adjusted life-years (QALYs) and $80,000 per patient over

233 Outcome Measures: Discounted quality-adjusted life-years (QALYs) and discounted costs.

234 t is also unclear how they relate to quality-adjusted life-years (QALYs) and funding recommendations

235 veness outcome was the difference in quality-adjusted life-years (QALYs) between groups from baseline

236 rse events and subsequent costs, and quality-adjusted life-years (QALYs) for intensive control versus

237 Quality-adjusted life-years (QALYs) for use in cost-utility anal

238 ethnicity, to estimate undiscounted quality-adjusted life-years (QALYs) gained and net health system

239 tment of cardiovascular disease, and quality-adjusted life-years (QALYs) gained by treating previousl

240 odel to calculate costs incurred and quality-adjusted life-years (QALYs) gained following HCV treatme

241 The respective number of quality-adjusted life-years (QALYs) gained in the test and no-te

242 benefit (NHB), which was measured as quality-adjusted life-years (QALYs) gained or lost by investing

243 Quality-adjusted life-years (QALYs) gained, costs from the socie

244 tcome of lifetime societal costs per quality-adjusted life-years (QALYs) gained.

245 n was one influenza season; however, quality-adjusted life-years (QALYs) lost due to death during the

246 ion of 50%), the incremental gain in quality-adjusted life-years (QALYs) was determined using a 6-mon

247 In-trial quality-adjusted life-years (QALYs) were similar (2.28 vs. 2.27;

248 s were the number of HIV infections, quality-adjusted life-years (QALYs), and costs.

249 s (in 2015 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cost-effect

250 Outcome Measures: Incremental costs, quality-adjusted life-years (QALYs), and incremental cost-effect

251 ral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-ef

252 lth benefits expressed as discounted quality-adjusted life-years (QALYs), costs in US dollars, and co

253 Hospitalizations, quality-adjusted life-years (QALYs), costs, and incremental cost

254 Outcome Measures: Life-years, quality-adjusted life-years (QALYs), costs, heart failure hospit

255 Life-years (LYs), quality-adjusted life-years (QALYs), direct medical expenditure,

256 mes and Measures: Lifetime costs and quality-adjusted life-years (QALYs), discounted at 3% annually.

257 t cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mammograms,

258 ints were survival, life expectancy, quality-adjusted life-years (QALYs), number and percentage of ov

259 Quality-adjusted life-years (QALYs), total costs (in US dollars

260 HIV incidence, mortality, costs and quality-adjusted life-years (QALYs).

261 ed health and social care costs with quality-adjusted life-years (QALYs).

262 The primary outcome measure was quality-adjusted life-years (QALYs).

263 fectiveness was measured in terms of quality-adjusted life-years (QALYs).

264 omes were measured in life-years and quality-adjusted life-years (QALYs).

265 benefit of 0.15 life-years and 0.11 quality-adjusted life-years (QALYs).

266 athogenic variant, in life-years and quality-adjusted life-years (QALYs).

267 States dollars) to the difference in quality-adjusted life-years (QALYs).

268 rage lifetime costs, life-years, and quality-adjusted life-years (QALYs).

269 more effective than THW in terms of quality-adjusted life-years (QALYs; +0.013 QALY/patient) but mor

270 ge in HIV prevalence, and discounted quality-adjusted life years [QALYs]), and incremental cost-effec

271 benefits (6.034 to 6.221 discounted quality-adjusted life-years [QALYs] per patient with monitoring

272 the discounted cost, effectiveness (quality-adjusted life-years [QALYs]), and incremental cost-effec

273 mate health care costs and outcomes (quality-adjusted life-years; QALYs) using data from the meta-ana

274 uality-adjusted life-year to $150000/quality-adjusted life-year range frequently cited as cost-effect

275 dence, prevalence, mortality, and disability-adjusted life-years rates tend to decline from 1990 to 2

276 igatran were $20 486 and $23 422 per quality-adjusted life year, respectively.

277 less effective (8.44, 8.54, and 8.59 quality-adjusted life years, respectively) and more costly.

278 ality-adjusted life-year and $662978/quality-adjusted life-year, respectively, over 2 years.

279 ers to be between $10 and $45 per disability-adjusted life-year saved.

280 , which was $142 to $182 less per disability-adjusted life-year than TTT or hybrid strategies.

281 ortality by 10-20%, at a cost per disability-adjusted life-year that is as low as any existing health

282 -term stroke care and an increase in quality-adjusted life-years, thereby supporting more widespread

283 n in this trial is within the $50000/quality-adjusted life-year to $150000/quality-adjusted life-year

284 as genuine, the incremental cost per quality-adjusted life year was pound56,811 in the base case anal

285 se was pound156 per person; cost per quality-adjusted life-year was pound9549 with the EQ-5D ( pound1

286 fectiveness ratio below $100,000 per quality-adjusted life year were considered cost effective.

287 total of 8.5 (2.8, 19.2) million disability-adjusted life years were related to SSB intake (4.5% of

288 Quality-adjusted life-years were also calculated.

289 Changes in quality-adjusted life-years were assessed with utilities determi

290 Quality-adjusted life-years were similar between the groups (tre

291 Quality-adjusted life-years were virtually identical in all the

292 pounds, pound) and health utilities (quality-adjusted life years) were used to calculate mean increme

293 vice costs and benefits (measured as quality-adjusted life-years) were estimated.

294 injuries, and risk factors using disability-adjusted life-years, which need a set of disability weig

295 emedicine in the ICU to extend 0.011 quality-adjusted life years with an incremental cost of $516 per

296 The discounted quality-adjusted life years with UDCA and OCA+UDCA were 10.74 an

297 ent utility (11.5 vs 11.4 discounted quality-adjusted life years) with lower total cost ($52.5K vs $7

298 within accepted US norms ($53925 per quality-adjusted life year, with 98% likelihood of meeting a $10

299 le cause of mortality and loss of disability-adjusted life years worldwide, and a substantial portion

300 e of the main causes of death and disability-adjusted life-years worldwide.